PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Levocloperastine→

Levocloperastine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
132301-89-4
Molecular formula
C20H24ClNO
Molecular weight
329.9 g/mol
Drug class
Non-opioid antitussivecentral and peripheral cough-reflex suppressant
Mechanism of action
The levorotatory isomer of cloperastine. It has described central effects at the medullary cough centre and peripheral effects on tracheobronchial cough receptors. Mechanistic data remain limited; cloperastine also has antihistaminic and papaverine-like smooth-muscle effects.
Indications / reported uses
  • Symptomatic relief of non-productive cough associated with respiratory tract conditions in countries where levocloperastine-containing products are authorised.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11060423/ · https://pubmed.ncbi.nlm.nih.gov/?term=levocloperastine+clinical+trial · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Levocloperastine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levocloperastine Permitted Daily Exposure (PDE) report (the Levocloperastine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levocloperastine Occupational Exposure Limit (OEL) report (the Levocloperastine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.